Replies to post #741131 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

YA II PN, Ltd. should definitely do DD on NWBO before providing the best financing. Which experts should YA II PN, Ltd. reach first for consulting?

I would think the experts should be those who just published the paper on a rGBM trial run by the company which has YA II PN, Ltd as the only institutional investor.
https://fintel.io/so/us/Nbio

Here is the paper about the trial run by NBIO. The two authors published several papers in which the keyword 'DCVax-L' was explicitly mentioned. Santosh Kesari was even among the coauthors in two papers about the p3 trial.

The longs are going to embrace for a great year of 2025!

A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases

Jose Carrillo, Jaya Mini Gill , Charles Redfern, Ivan Babic, Natsuko Nomura, Dhaval K. Shah, Sean Carrick, and Santosh Kesari

https://academic.oup.com/noa/article/6/1/vdae166/7795944?login=false

Santosh Kesari
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent GlioblastomaA Phase 3 Prospective Externally Controlled Cohort Trial
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847


First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
https://link.springer.com/article/10.1186/s12967-018-1507-6

Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
Daniela A. Bota, Thomas H. Taylor, David E. Piccioni, Christopher M. Duma, Renato V. LaRocca, Santosh Kesari, Jose A. Carrillo, Mehrdad Abedi, Robert D. Aiken, Frank P. K. Hsu, Xiao-Tang Kong, Candace Hsieh, Peter G. Bota, Gabriel I. Nistor, Hans S. Keirstead & Robert O. Dillman
https://link.springer.com/article/10.1186/s13046-022-02552-6

Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines
Feng Lin, Emma Z. Lin, Misa Anekoji, Thomas E. Ichim, Joyce Hu, Francesco M. Marincola, Lawrence D. Jones, Santosh Kesari & Shashaanka Ashili
https://link.springer.com/article/10.1186/s12967-023-04724-0

Progress in Neurological Surgery
Intracranial Gliomas Part III - Innovative Treatment Modalities
Mikhail F. Chernov; Yoshihiro Muragaki; Ian E. McCutcheon; Santosh Kesari
https://karger.com/books/book/260/chapter-abstract/5178837/Cell-Based-Immunotherapy-of-Gliomas?redirectedFrom=fulltext


Jose Carrillo

Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
Daniela A. Bota, Thomas H. Taylor, David E. Piccioni, Christopher M. Duma, Renato V. LaRocca, Santosh Kesari, Jose A. Carrillo, Mehrdad Abedi, Robert D. Aiken, Frank P. K. Hsu, Xiao-Tang Kong, Candace Hsieh, Peter G. Bota, Gabriel I. Nistor, Hans S. Keirstead & Robert O. Dillman
https://link.springer.com/article/10.1186/s13046-022-02552-6


Enhanced Progression-Free Survival in a Phase 2 Trial of Personal Dendritic Cell Vaccines in Patients with Newly Diagnosed Glioblastoma
Piccioni DE 1, Duma CM2 , Kesari S3, LaRocca RV4, Aiken RD5 , Taylor TH6, Carrillo JA2,3 , Abedi M7, Nistor GI 8 , Keirstead HS8, Dillman RO6,8*, Bota DA 6
https://pdfs.semanticscholar.org/6782/affbff554b427e1b14fd13ff88af8da535ce.pdf


Therapeutic Immunization against Glioblastoma
Virgil E. J. C. Schijns 1,2,3,*, Chrystel Pretto 2, Anna M. Strik 1, Rianne Gloudemans-Rijkers 1, Laurent Devillers 2, Denis Pierre 2, Jinah Chung 4, Manisha Dandekar 4, Jose A. Carrillo 5,6, Xiao-Tang Kong 4,5,6, Beverly D. Fu 4,6, Frank P. K. Hsu 4,5, Florence M. Hofman 7, Thomas C. Chen 8, Raphael Zidovetzki 9, Daniela A. Bota 4,5,6 and Apostolos Stathopoulos 1,2,3,8,1

https://www.mdpi.com/1422-0067/19/9/2540

[GoodGuyBill]

EXACTLY!!!!

For posters like Manibioteg, the real question he should ask himself is,"What kind of an investment banking group would loan a pre-revenue biotech company on the OTC at .25 cents per share, $5,000,000 for 13 months for a 7% placement fee with no payments due AND commit for a $50,000,000 "standby" line after the $5 million repay for 24months and agree to accept NWBO common shares at a slight discount to the then current price without believing that the company represents a solid, going concern value for the next several years"??????

AND the answer should be, an investment banker that is confident that the company will receive MHRA regulatory approval and many more RA's from multiple other countries AND have the MTD in the company's current lawsuit denied opening the door for Discovery with an eventual settlement or a major Trial Victory. Yorkville is that banker, who, by the way, underwrote a $38,000,000 offering for DJT's social media company that was also attacked by Ken Griffin's Citadel taking theTruth Social from the $50's to $12 . That's a $93,000,000 bet on 2 companies attacked by Citadel.

NWBO is across the finish line and Citadel and Virtu are looking very puny!!!

Cheers,

BB